CYLD

Across TCGA pan-cancer cohorts, CYLD mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CYLD data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CYLD mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CYLD expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where CYLD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.851	0.625	<.001	23	view →
LSCC	OS	Tertile	II,III,IV	0.687	1.000	.013	13	view →
PDAC	OS	Median	III,IV	0.316	0.537	.030	6	view →
CCRCC	DFS	Median	II,III,IV	0.746	0.488	.018	6	view →
HNSC	OS	Tertile	All	0.954	0.856	.045	1	view →
GBM	OS	Quartile	All	0.908	0.736	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CYLD–LUAD (DFS)

Open the LUAD breakdown →